Christensen group: Cellular and molecular biology of myocardial hypertrophy

Christensen group

We aim to develop novel therapeutic approaches and better diagnostic tools for heart failure through new knowledge about molecular mechanisms involved.

 

 

In particular, we study the concept that cardiac proteoglycans are active and central signal mediators of myocardial remodeling. Proteoglycans are highly glycosylated proteins localized to the cell membranes and the extracellular matrix (ECM).

By examining the unique properties of transmembrane proteoglycans we have discovered that the proteoglycan syndecan-4 is a mechanical stress-sensor in cardiomyocytes and cardiac fibroblasts and involved in signalling causing heart failure. One important ECM-localized molecule is lumican and we have shown that it regulates cardiac remodelling and heart failure. Currently we are testing promising drugs to treat heart failure by targeting mechanisms identified by our group. The ultimate goal of our research is to improve the well-being and prognosis of patients.

 

The work in this group is supervised by professor Geir Christensen. The group consists of scientists from IEMR that collaborate closely with Department of Thoracic Surgery (Professor Theis Tønnessen) and Department of Cardiology at Oslo University Hospital (Professor Lars Gullestad). In addition to top-of-the-range international scientists from Harvard, Johns Hopkins, among others, who are world leading in their field.

Group Leader

Geir Christensen

Group Leader & Professor

Group members

Andreas Romaine

Postdoctoral fellow

Anett Hellebø Ottesen

Postdoctoral fellow

Athiramol Sasi

Researcher without PhD

Camilla Udjus

Doctoral Research Fellow

Francesca Lockwood

Doctoral Research Fellow

Maria Vistnes

Postdoctoral fellow, Resident

Latest publications

view all >
Romaine A, Melleby AO, Alam J, Lobert VH, Lu N, Lockwood FE, Hasic A, Lunde IG, Sjaastad I, Stenmark H, Herum KM, Gullberg D, Christensen G (2022)
Integrin α11β1 and syndecan-4 dual receptor ablation attenuates cardiac hypertrophy in the pressure overloaded heart
Am J Physiol Heart Circ Physiol
PubMed 35522553 DOI 10.1152/ajpheart.00635.2021
Berge K, Brynildsen J, Røysland R, Strand H, Christensen G, Høiseth AD, Omland T, Røsjø H, Lyngbakken MN (2022)
Prognostic value of cardiac biomarkers and National Early Warning Score 2 in acute dyspnoea
Open Heart, 9 (1)
PubMed 35387863 DOI 10.1136/openhrt-2021-001938
Gløersen M, Steen Pettersen P, Neogi T, Jafarzadeh SR, Vistnes M, Thudium CS, Bay-Jensen AC, Sexton J, Kvien TK, Hammer HB, Haugen IK (2022)
Associations of Body Mass Index With Pain and the Mediating Role of Inflammatory Biomarkers in People With Hand Osteoarthritis
Arthritis Rheumatol, 74 (5), 810-817
PubMed 35137553 DOI 10.1002/art.42056
Udjus C, Sjaastad I, Hjørnholm U, Tunestveit TK, Hoffmann P, Hinojosa A, Espe EKS, Christensen G, Skjønsberg OH, Larsen KO, Rostrup M (2022)
Extreme altitude induces divergent mass reduction of right and left ventricle in mountain climbers
Physiol Rep, 10 (3), e15184
PubMed 35146955 DOI 10.14814/phy2.15184
Carlson CR, Aronsen JM, Bergan-Dahl A, Moutty MC, Lunde M, Lunde PK, Jarstadmarken H, Wanichawan P, Pereira L, Kolstad TRS, Dalhus B, Subramanian H, Hille S, Christensen G, Müller OJ, Nikolaev V, Bers DM, Sjaastad I, Shen X, Louch WE, Klussmann E, Sejersted OM (2021)
AKAP18δ Anchors and Regulates CaMKII Activity at Phospholamban-SERCA2 and RYR
Circ Res, 130 (1), 27-44
PubMed 34814703 DOI 10.1161/CIRCRESAHA.120.317976
view all >